Conformational diversity and protein-protein interfaces in drug repurposing in Ras signaling pathway
© 2024. The Author(s)..
We focus on drug repurposing in the Ras signaling pathway, considering structural similarities of protein-protein interfaces. The interfaces formed by physically interacting proteins are found from PDB if available and via PRISM (PRotein Interaction by Structural Matching) otherwise. The structural coverage of these interactions has been increased from 21 to 92% using PRISM. Multiple conformations of each protein are used to include protein dynamics and diversity. Next, we find FDA-approved drugs bound to structurally similar protein-protein interfaces. The results suggest that HIV protease inhibitors tipranavir, indinavir, and saquinavir may bind to EGFR and ERBB3/HER3 interface. Tipranavir and indinavir may also bind to EGFR and ERBB2/HER2 interface. Additionally, a drug used in Alzheimer's disease can bind to RAF1 and BRAF interface. Hence, we propose a methodology to find drugs to be potentially used for cancer using a dataset of structurally similar protein-protein interface clusters rather than pockets in a systematic way.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Scientific reports - 14(2024), 1 vom: 12. Jan., Seite 1239 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sayin, Ahenk Zeynep [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5W6YA9PKKH |
|---|
| Anmerkungen: |
Date Completed 15.01.2024 Date Revised 16.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-023-50913-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367071428 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367071428 | ||
| 003 | DE-627 | ||
| 005 | 20240116232017.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-023-50913-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1261.xml |
| 035 | |a (DE-627)NLM367071428 | ||
| 035 | |a (NLM)38216592 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sayin, Ahenk Zeynep |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Conformational diversity and protein-protein interfaces in drug repurposing in Ras signaling pathway |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.01.2024 | ||
| 500 | |a Date Revised 16.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a We focus on drug repurposing in the Ras signaling pathway, considering structural similarities of protein-protein interfaces. The interfaces formed by physically interacting proteins are found from PDB if available and via PRISM (PRotein Interaction by Structural Matching) otherwise. The structural coverage of these interactions has been increased from 21 to 92% using PRISM. Multiple conformations of each protein are used to include protein dynamics and diversity. Next, we find FDA-approved drugs bound to structurally similar protein-protein interfaces. The results suggest that HIV protease inhibitors tipranavir, indinavir, and saquinavir may bind to EGFR and ERBB3/HER3 interface. Tipranavir and indinavir may also bind to EGFR and ERBB2/HER2 interface. Additionally, a drug used in Alzheimer's disease can bind to RAF1 and BRAF interface. Hence, we propose a methodology to find drugs to be potentially used for cancer using a dataset of structurally similar protein-protein interface clusters rather than pockets in a systematic way | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a tipranavir |2 NLM | |
| 650 | 7 | |a ZZT404XD09 |2 NLM | |
| 650 | 7 | |a Indinavir |2 NLM | |
| 650 | 7 | |a 5W6YA9PKKH |2 NLM | |
| 650 | 7 | |a HIV Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Proteins |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a Pyrones |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 700 | 1 | |a Abali, Zeynep |e verfasserin |4 aut | |
| 700 | 1 | |a Senyuz, Simge |e verfasserin |4 aut | |
| 700 | 1 | |a Cankara, Fatma |e verfasserin |4 aut | |
| 700 | 1 | |a Gursoy, Attila |e verfasserin |4 aut | |
| 700 | 1 | |a Keskin, Ozlem |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 14(2024), 1 vom: 12. Jan., Seite 1239 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:1 |g day:12 |g month:01 |g pages:1239 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-023-50913-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 1 |b 12 |c 01 |h 1239 | ||